Altheos (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Altheos

Pioneering novel treatments with promising small molecule drugs for glaucoma, supported by significant Series A funding.

Founded 2010 Series A Total: $32.50M Biotechnology, Health Care

Altheos is an early-stage biopharmaceutical company based in the San Francisco Bay area, focusing on the development of innovative small molecule drugs for the treatment of glaucoma. The company gained significant traction in March 2010, securing $20 million in Series A financing led by Bay City Capital and supported by Novo A/S, Canaan Partners, Life Science Angels, and Atheneos Capital. This substantial investment is earmarked for the advancement of ATS907, a selective Rho-kinase inhibitor intended for the topical treatment of glaucoma. Notably, Altheos licensed this promising compound from a Japanese pharmaceutical company and has a broad portfolio of highly effective compounds designed specifically for glaucoma treatment. Overall, Altheos seems to have garnered significant support from key players in the industry, and its focus on pioneering novel treatments for glaucoma positions it well for success in the healthcare and biotechnology sectors. The $12.50 million Series A investment further indicates continued confidence in the company's potential, with Novo Holdings, Canaan Partners, and Bay City Capital demonstrating their ongoing commitment to Altheos' development. This strategic support, combined with the promising pipeline of small molecule drugs, positions Altheos as a compelling player in the quest for innovative glaucoma treatments.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	••••••	3		09 Feb 2012
Series A	••••••	5	•••• ••••	05 Apr 2010

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

••••••

09 Feb 2012

Series A

••••••

•••• ••••

05 Apr 2010

FAQ About Altheos

Pioneering novel treatments with promising small molecule drugs for glaucoma, supported by significant Series A funding.

Altheos was founded in 2010.

Altheos operates in the following industries: Biotechnology, Health Care.

Altheos has completed 2 funding rounds, raising a total of $32.50M. The latest funding stage is Series A.

Top alternatives and competitors to Altheos include Transport Pharmaceuticals, Foamix Pharmaceuticals, Sienna Biopharmaceuticals, Hexima Limited (ASX:HXL), Qlaris Bio, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Altheos and Transport Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Altheos

General Information

Track Altheos

Discover More

About Altheos

Funding Rounds & Investors (2)

Altheos Alternatives & Competitors

FAQ About Altheos

Don't just browse. Track.